Weight Loss Achieved by Overweight and Obese Subjects Entering the Lipotrim® Weight Loss Programme Monitored by Pharmacists in England

Thurnham David I1*, Beeson Valerie2 and Kreitzman Stephen N2
1Northern Ireland Centre for Food & Health, School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK
2Howard Foundation Research Ltd, Downing Park, Station Road, Swaffham Bulbeck CB25 0NW, UK

Abstract

The objective of this report was to assess the results of a weight-loss programme managed by pharmacists since obesity and type-2 diabetes are serious problems in the UK. We evaluated the service provided by pharmacists in the UK to manage and continuously monitor a very low energy diet (VLED) program based on Lipotrim® for overweight and obese people who wished to lose weight. Between 2008 to 2013, 57 (~3%) of 2000+ pharmacies offering the service elected to utilise online tracker software instead of paper records. Extrapolation of the subject numbers from this subset to the full population presenting to participating pharmacies for weight management yields an estimate of more than 300,000 people. 8724 overweight people voluntarily enquired about the weight loss program at the 57 pharmacies. Approximately 50% of these people completed at least two full weeks and their information was analysed in this report. Of the 50% who completed two weeks, 30% (1077 women, 241 men), displayed a period of linear decline in weight and at a mean duration of ~60 days, mean weight loss in women was 12 kg (-12.6% initial weight) and in men was 16.5 kg (-13.8%). The remaining 70% (2487 women, 540 men) lost 8.0 and 11.5 kg over 104 and 122 days respectively. In conclusion, weight losses in those people who persisted in the program will have a public health benefit and potentially reduce their risk of co-morbidities such as diabetes. Pharmacists in the UK are ideally placed to provide and monitor weight loss programs for overweight people.

Keywords: Obesity; VLED; Weight loss; Pharmacies; Body mass index

Abbreviations: VLED: Very low energy diet; BMI: Body Mass Index

Introduction

Obesity is closely associated with diabetes, high blood pressure, joint pain and deterioration, stroke, some cancers and heart disease [1,2] and the problems are of increasing concern in developed [3,4] and developing [5] countries. Obesity is assessed using the body mass index (BMI, weight/height squared, kg/m^2). Values greater than 25 are associated with a greater risk of diabetes (specifically type-2 diabetes), cardiovascular disease and cancer and persons with BMIs >40 (class III obesity) have substantially increased rates of mortality [3]. Currently persons with a BMI between 35 and 40 kg/m^2 and already having a significant disease such as type-2 diabetes can be considered for bariatric surgery. However, bariatric surgery is an expensive procedure and not without its own problems.
Complication rates are high and can be very serious [6].

A reduction in weight by overweight people has been shown to reduce the risk of diabetes [7,8]. The natural way to lose weight is by reducing food, or specifically calorie, intake; that is dieting and/or an increase in calorie expenditure i.e. physical activity. Furthermore dieting is relatively cheap and does not carry any surgical risks. Unfortunately, successful dieting is notoriously difficult as indicated by the number and variety of dieting methods available to the general public. Hospital studies have shown that successful weight loss can be achieved using structured weight loss programmes using very low energy diets (VLED) [9] and that long term weight-loss maintenance is significantly greater than that following successful hypo-energetic diets in both men and women at 4 to 5 years of follow-up [10]. Although hospital studies of the effects of VLEDs on overweight people have been shown to be a highly efficacious method of reducing body weight [9], being overweight or obese is usually not a clinical condition and hospital treatment using VLEDs is inappropriate and rarely available. Nevertheless, successful dieting requires assistance by family members or professionals or both as well as self-control.

In this paper we describe an evaluation of a service provided by English pharmacists in assisting overweight and obese people to lose weight using structured weight-loss programme based on a product known as Lipotrim®. We report weight losses achieved by two groups of these subjects; those who stick more rigidly to the weight loss plan and those whose dietary compliance is more erratic. We show that successful weight loss by both groups was achieved.

### Materials and Methods

#### Data collection

From March 2001 an expanding list of pharmacists, currently over 2000, have offered a professional service to assist in obesity prevention and treatment where overweight people wish to lose weight. Trained pharmacists supervise and monitor dieters using the Lipotrim® formula foods and, importantly, they can also offer a follow-up weight maintenance program and supervision but that is not the subject of this report. Lipotrim® is sold through pharmacies throughout the United Kingdom and data on weight, height, age and sex are recorded by the pharmacists for those people who voluntarily enrol in the programme. We emphasize, participation in the weight loss programme by members of the public is entirely voluntary i.e., they continue for as long or as little as they wish. Participants buy Lipotrim® products from the pharmacists and attend weekly for professional monitoring; recording of weight, reporting of any changes in their medical condition and obtaining enough formula for a subsequent week. At the time of the assessment reported in this paper, 57 (~3%) of the pharmacies' records were kept on-line using Lipotrim® patient tracker secure software (Backup Data Ltd 15 Sable Close, Cambridge, CB1 9YX). These data are used by the pharmacists to monitor a subject's progress and the on-line service permits the suppliers to assess the collective success of the pharmacy's service in weight management.

Height and weight were recorded by the individual pharmacists using equipment supplied at no cost by Howard Foundation Research Ltd. Weights were recorded using precision scales (UC-321PL, A & D Medical, 24-26 Blacklands Way, Abingdon Business Park, Abingdon, Oxfordshire OX14 1DY). Height was measured by a Seca 206 Roll up Measuring Tape (Seca, 40 Barn Street, Birmingham B5 5QB).

Names and addresses, recorded at the pharmacy as part of the pharmacy's records, were not available beyond the specific pharmacy, but subjects were allocated a unique number so a subject's weight loss data could be included in the overall outcome assessments. All anonymized data was made available online to The Howard Foundation Research Ltd. Subjects who did not complete 2 full weeks were removed from the analysis. This paper will report only the data collected on the tracker database from English pharmacies over the six years from March 2008 to May 2013. These data were collected from 3564 female and 781 male weight loss records 97.5% of which were accumulated by 57 pharmacies who submitted records for four or more subjects on line between 2008 and 2013.
Dietary regimen

Lipotrim® is a very low energy diet (VLED) and the components contributing to the energy intake are shown in Table 1. A daily serving contains all the required essential amino acids, essential fatty acids, trace elements, vitamins and minerals in amounts which meet 100% of the recommended daily allowance. Instructions on the use of the product are provided by the pharmacy and also accompany the packaging. The products are intended as a total food replacement and for full compliance, additional food is not permitted. The product is designed to reduce energy intake to the minimum consistent with complete nutrition and is provided as sachets of different flavoured powders and as flapjacks with two flavours. Female participants are instructed to consume 3 sachets a day or two sachets and a flapjack and for men, two larger sachets per day or 1 larger sachet and 2 flapjacks. Constituents of the sachets for men and women are identical in composition but men, who have higher nutritional requirements because of a higher metabolic rate due to a greater muscle mass, have more of the diet (Table 1) but the flapjacks are the same. Three sachets for a woman provide 1785 kJ (425 kcal) and two sachets for a man provide 2380 kJ (567 kcal). If participants adopt the flapjack option, total daily energy consumed is 1991 and 2381 kJoules (474 and 675 kcal) for women and men respectively. All the products are gluten free and suitable for vegetarians. Sachets can be prepared as a drink (hot or cold) or as a mousse and guidance is given to ensure that subjects using Lipotrim® as a total food replacement consume at least 2 L of water per day. The Lipotrim® program comprises three distinct phases to ensure that the subjects achieve and maintain weight loss: strict weight loss, transition and maintenance. Only weight loss results are presented here.

Ethical considerations and participation in the weight-loss programme

This paper is an evaluation of the program provided by pharmacies and as such does not require ethical approval in the UK [11]. The subjects voluntarily entered the weight-loss programme and gave their informed consent to the use of their anthropometric and medical history results by signing the following statement.

Table 1: Daily recommended energy-contributing food components by men and women enrolled in the Lipotrim® program1.

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 Sachets</td>
<td>2 Sachets 1 Flapjack</td>
</tr>
<tr>
<td>Energy (kcal)</td>
<td>425</td>
<td>475</td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>1785</td>
<td>1992</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>43</td>
<td>42.3</td>
</tr>
<tr>
<td>Carbohydrate (g)</td>
<td>45</td>
<td>38.3</td>
</tr>
<tr>
<td>Sugar (g)</td>
<td>44</td>
<td>34.6</td>
</tr>
<tr>
<td>Starch (g)</td>
<td>1.2</td>
<td>3.9</td>
</tr>
<tr>
<td>Fat (g)</td>
<td>7</td>
<td>14.3</td>
</tr>
<tr>
<td>Saturates (g)</td>
<td>2.3</td>
<td>3.2</td>
</tr>
<tr>
<td>Monounsaturated (g)</td>
<td>1.6</td>
<td>4.8</td>
</tr>
<tr>
<td>Polyunsaturated (g)</td>
<td>3.1</td>
<td>6.3</td>
</tr>
<tr>
<td>Cholesterol (g)</td>
<td>17</td>
<td>11.4</td>
</tr>
</tbody>
</table>

1Sachets contain powdered formula in a variety of flavours which can be prepared as a hot or cold beverage or as a mousse. The two columns for each sex represent alternative dietary options.
2Note sachets for men are larger than those for the women.
Statistics and calculations

Statistics were done using SPSS version 19. Most data were normally distributed and are therefore shown as means and standard deviations. The only exception was the days duration of dieting which was positively skewed. Differences in anthropometric data between the sexes was determined by independent ‘t’ tests. Bivariate analyses and multiple linear regression was used to investigate relationships between the anthropometric data and weight loss. To identify fully-compliant dieters and calculate the kjoules (kcal) deficit per day, weights were plotted against days on the program for each individual. Fully-compliant dieters were identified when the linear correlation of at least 5 successive weekly differences in body weights plotted against days had an $r^2$ greater than 0.9. For these subjects the computer algorithm calculated the weight loss in g/day for the linear region of the diet plot after the first month of dieting. During this period, weight loss is predominantly fat at 37800 kjoules (9000 kcal)/kg. However, this weight loss (energy depletion) occurs in the face of the energy intake from the VLED, therefore, the total daily energy utilisation (i.e. deficit) during the linear period is calculated as follows.

Estimated energy deficit

\[(kcal)/day = (weight loss \times 9 \text{ kcal/g}) + \text{VLED}\]

Where: weight loss is in g/day from the regression equation

VLED is 425 and 567 kcal in Lipotrim® for women and men respectively

\[\text{kJoules} = \text{kcal} \times 4.2\]

Results

Anthropometric and limited demographic information was available from the 4344 subjects (3563 women and 781 men) who voluntarily started the Lipotrim® weight loss program and continued for variable lengths of time in excess of two weeks. These data represent approximately 50% of subjects registering on the program at a subset of 57 pharmacies, since entries for subjects who did not complete two full weeks were removed from the analysis. The subjects not included were not necessarily dieting failures. Some subjects elected to try alternative methods of weight loss, some decided to postpone proceeding for personal reasons or, after learning what was involved for participation, decided the diet was not for them. The valid data were subdivided into two groups, those whose weights fluctuated over the period of enrolment (erratic dieters, 2486 women and 540 men) and those whose records showed a period of linear decline in weight with time (compliant dieters, 1077 women and 241 men).

Table 2 shows the weight loss data for the compliant dieters. Mean ages of the women were slightly greater than those of the men (P=0.042) and the age range stretched from 18 years to 74 and to 75 years in women and men respectively. Starting weights and BMIs of the men were both significantly higher than those of the women (P<0.000). There was no difference in the duration on the weight loss program in the two sexes (p=0.588). The mean weight loss in the women (12 kg) was less than that in the men (16.5 kg; P<0.000) and mean weight loss as a percentage of initial weight was 12.6% in the women and slightly greater (13.8%, P=0.014) in the men. The mean weight loss over the total period of dieting was 226 or 324 g/day in men and women respectively. Approximately 16% (n=209) of these
In the compliant dieters, the mean estimated energy deficits per day during the linear phase of the diet plan were 8585 and 12,262 kJ (2044 and 2911 kcal) in women and men respectively. To calculate the mean daily weight loss from the energy deficit during the linear phase of dieting, energy intakes from the VLED were first subtracted (1619, 2344 kcal) and these values divided by 9 (energy value of fat) to give 180 and 260 g/day in women and men respectively. That is the mean energy deficit per 100 g weight loss was approximately the same; 3776 and 3788 kJ (899 and 902 kcal) in women and men respectively. Although the mean energy deficits were approximately the same as the accepted values for the energy required for maintenance of weight [12] the standard deviations attached to these values are large for both women and men and indicate considerable variability in the estimated energy deficit needed for weight loss.

Table 3 shows weight loss data in those with a more erratic weight decline indicating somewhat less than strict adherence to the VLED protocol. There were no major differences in ages or anthropometric details between these dieters and those displaying linear weight loss. Mean dieting duration times however was almost twice as long in the erratic dieters; 104 and 122 days in women and men respectively. The mean weight loss over this time was 8 kg in the women and 12.5 kg in the men, a drop of 9 and 10% respectively of starting weights. Only 5% (n=158) lost more than 20% of their initial weight but the maximum weight lost by any dieter was 124 and 66.4 kg in the women and men respectively.

In the more compliant dieters we explored the relationships between the anthropometric factors and the daily estimated energy deficits (Table 4). Height and initial and end weights were positively related to the calories lost per day while age and dietary duration were negatively related. Multiple linear regression of the data showed that these variable explained 31% of the variance in men and 24% in the women. The principal factors in both sexes were approximately equal contributions from an inverse relationship with the duration of dieting and a positive relation with initial weight. Together these variables explained 20% and 12%...
of the variance in the men and women respectively. In both dieting groups, the final mean BMI fell from around 34-35 to 30-31. It was of interest to know how subjects with less severe obesity responded to the diet. We identified overweight, but not yet obese subjects with BMIs between 25 and 30 and found in both groups the effect of the diet was to reduce BMIs to a mean value of approximately 25 (Table 5). That is approximately half of the subjects in this specific group achieved the healthy weight range.

**Discussion**

This study provides documentation of the successful weight losses in overweight people who voluntarily chose to take part in a weight-loss program managed by pharmacists. They had not incurred the risks and costs of bariatric surgery and did not have the assistance of a dedicated hospital VLED program if one was available. The data suggest that close adherence to the Lipotrim® diet by dieters in their own homes reduced mean weights in women and men by 12 and 16.5 kg respectively; that is reductions of 12.6% and 13.8% of starting weights in approximately two months. Even women and men who did not adhere strictly to the recommended program and consequently did not achieve a linear weight loss, were nevertheless able to reduce their weights by 8 and 12.5 kg. These reductions represented 9 and 10%, respectively of their starting weights but the time taken was 70-100% longer than that in the compliant dieters.
At the time of this assessment 8724 overweight people registered for the weight loss program at 57 of 2000+ pharmacies, which facilitated this evaluation of the program. Extrapolation of the subject numbers from this subset to the full population presenting to participating pharmacies for weight management yields an estimate of over 300,000 people. From discussions with participating pharmacists we can reliably assume that at least half this number will have achieved weight loss in excess of 9-10% of their initial body weights in two to four months.

There is a close association of overweight with a higher risk of diabetes [6] and weight loss has been repeatedly shown to reduce the prevalence of diabetes and lower cardio-metabolic risk [9,13]. In a 10 year community study of weight gain and loss in 1929 overweight people, there were 251 incident cases of diabetes. Workers found that relative to those with stable weight, each kg of weight loss annually was associated with a 33% lower risk of diabetes in the subsequent 10 years whereas one kg of weight gain was associated with a 49% increased risk of developing diabetes [7].

Likewise, workers studying weight, diabetes prevalence and mortality over 30 years from 1980 to 2010 in Cuba during an economic crisis and a subsequent recovery, found that a 5.5kg weight loss over the whole population during the crisis was associated with rapid declines in diabetes and heart disease which rebounded once economic conditions improved [8]. Thus weight loss in the community can have long-term beneficial effects on health and it is important that the progression to obesity is prevented. These and other studies show that the adverse health consequence from excess weight can begin long before weight reaches a BMI of 30, the so called ‘obesity boundary’ [14,15]. This is particularly true for certain ethnic populations, especially South Asians who have the same risk of diabetes at BMI 24 as white populations at BMI 30 [16].

For overweight patients, and especially those at higher levels of obesity, losing weight can be extremely difficult and standard approaches to weight loss have been less effective than VLEDs [17]. Many obese patients fail because they are attempting to control addictive behaviour while continuing to use the ‘substance of abuse’ – food. This approach does not work for alcohol, tobacco or drugs and it rarely works for food [18]. For seriously overweight people, the most effective treatment is to totally stop the substance of abuse, which is why a total food replacement program is much more effective than trying to cut down on conventional food intake [19].

From a physiological point of view the human body does not require food as such but essential nutrients, specific chemical compounds of which people require a sufficient supply to stay healthy together with a source of fibre to provide bulk. These nutrients are normally supplied in the diet but as there is no single food that exactly matches all human nutritional needs, it is necessary ordinarily to obtain them from

---

**Table 5:** Effects of the very low energy diet on the BMI of subjects with an initial BMI between 25-30.

<table>
<thead>
<tr>
<th></th>
<th>Compliant dieters</th>
<th>Erratic dieters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women</td>
<td>Men</td>
</tr>
<tr>
<td><strong>Numbers</strong></td>
<td>237</td>
<td>30</td>
</tr>
<tr>
<td><strong>Percent of total number</strong></td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td><strong>Initial BMI ≥25 &amp; &lt;30</strong></td>
<td>27.99 (1.28)</td>
<td>28.5 (1.11)</td>
</tr>
<tr>
<td><strong>Final BMI</strong></td>
<td>25.04 (1.48)</td>
<td>25.7 (1.25)</td>
</tr>
<tr>
<td><strong>Duration of dieting (days)</strong></td>
<td>45 (29)</td>
<td>41 (22)</td>
</tr>
<tr>
<td><strong>Number (%) of subjects with BMI&lt;25 following weight reduction</strong></td>
<td>161 (67%)</td>
<td>10 (33%)</td>
</tr>
</tbody>
</table>

1' Data shown are means and SD. Subjects with a marginally elevated initial BMI between ≥25 and <30 were identified in the two groups. Final BMIs are those reported at the time of the last reported weight.
a diverse range of foods. Obtaining the required complement of nutrients from common foods requires the consumption of many more calories than is consistent with rapid and substantial weight loss. The advantage of a total food replacement program is that nutrition is provided by an engineered formula that is nutritionally complete, allowing the dieter to remove the variable components (i.e., food) from his or her life while weight is lost and the medical consequences of the excess weight are relieved. The total food replacement regime is arguably the only non-surgical means by which those who consume excessive amounts of food may avoid the stimulus that perpetuates their weight problem. The most salient fact that weight loss in overweight or obese people achieves is a reduced risk of diabetes or remission of established diabetes.

A limitation of this report is that we only have weight loss records for 50% of those subjects who initially enquired about the Lipotrim® program and subsequently dieted with Lipotrim®. Participation in the program was entirely voluntary and does require firm commitment to the dietary regime. Prospective dieters are required to view, and sign that they have viewed, a DVD that fully details the program, its strict requirements and potential side effects. When the DVD is loaned to the potential dieter, the record is retained on the computer, but if the person does not undertake the program, there is no further data. Not all people are willing to undertake such a strict program, but it is usually not possible to determine the reasons why an individual declined the program. In addition because of the confidential nature of the program, no medical records were available to us beyond the initial medical questionnaire, so a further limitation of this report was the lack of evidence supporting the long term benefit to diabetic patients. Only two weight loss methods, bariatric surgery and VLED, reliably provide sufficient weight loss rapidly enough to enable long term glycemc control in diabetic patients [9] however since only diabetic patients whose doctor authorized suspension of medication were permitted to diet we can reasonably assume that restarting medication became unnecessary in most, if not all the type 2 diabetic patients discussed their treatment with their general practitioner and their treatment modified. It has been known for almost 40 years that excessive blood glucose concentrations fall in subjects on a VLED [20] and this was clearly shown by Henry and co-workers in obese subjects with type-2 diabetes whose blood glucose concentrations fell by 50% after 10 days on a VLED and there were further reductions on day 40 [9]. It is important therefore that overweight person with diabetes do not start a VLED program without first withdrawing blood glucose-reducing medication.

The information in this report was from subjects who were not part of a research program so they were not under any obligation to continue with the pharmacist. The last recorded weights illustrate that the more compliant dieters achieved appreciable weight loss in approximately two months on the VLED. Henry and colleagues achieved a mean weight loss of 10.5 kg (SD 0.4) after 40 days in 30 obese subjects who consumed 330 kcals/day [9]. The weight loss achieved by the subjects enrolled in the pharmacies for a mean duration of 60 days and who had slightly higher energy intakes, was 12 and 16.5 kg in the women and men respectively. That is weight loss by the pharmacy subjects was comparable with the more controlled hospital study of Henry and colleagues [9].

Any person receiving treatment for diabetes would not have started the VLED until the pharmacist had any person receiving treatment for diabetes would not have started the VLED until the pharmacist had

The effect of VLEDs on overweight people is a highly efficacious method of reducing body weight since the calories supplied are insufficient in all adults to meet even basal metabolic needs, regardless of size or activity. The body therefore has to draw on energy reserves to supply the needed calories. The total mean weight loss per day by the more compliant dieters was 226 and 324 g for the women and men respectively. However, during the linear phase of dieting when body fat is the principal tissue being consumed, weight loss per day was 180 and 260 g/day in women and men respectively. The average energy deficit needed to produce weight loss during the linear phase was approximately 4720 kJoules (1124 kcal) per 100 g weight loss in both women and men. It follows that if dieters should eat more than the recommended diet during the linear phase they will lose less weight and vice versa. However, deviations from the programme would lead to a loss of linearity and subjects would not have been included in the linear group. Nevertheless, small devia-
tions from the recommended diet programme as well as lifestyle and genetic factors may explain the wide standard deviations of the energy deficit needed to produce this weight loss. That is the energy deficits to produce weight loss in some people are much smaller than in others. It can be speculated that if people have only a small energy deficit when consuming the recommended VLED intake then it follows that a smaller number of calories may only be needed to regain that weight and vice versa. That is these data may provide some guidance for the pharmacist on the number of calories needed by their patients during weight maintenance when dieting has finished and they request advice to maintain their lower weight. Weight maintenance however was not a component of these studies.

**Conclusion**

Pharmacists in England who utilised the Lipotrim<sup>®</sup> VLED and also recorded the data on-line with the Lipotrim<sup>®</sup> Patient Tracker software, were approached by 8724 overweight people between March 2008 and May 2013. Fifty percent of these subjects (n=4344) voluntarily participated in the programme and successfully completed at least 2 weeks dieting. Of these, 30% (n=1318) achieved linear declines in weight over a mean duration of 60 days and the weight loss evidence suggests they were more compliant with the dietary program than the remaining 70% (n=3026). These subjects lost weight but dieted for almost twice as long. The data show that pharmacists supervising the Lipotrim<sup>®</sup> VLED in free-living, compliant overweight men and women were able to assist their subjects to lose mean weights of 12 kg in women and 16.5 kg in men. In the less-compliant subjects, mean weight losses of 8 and 11.5 kg in women and men respectively were obtained. From a public health viewpoint, overweight subjects who can adhere to a VLED can achieve sufficient weight loss to reduce their risk of type 2 diabetes and cardiovascular disease. Pharmacists are ideally placed to supervise a VLED program for the general public.

**Acknowledgements**

We acknowledge the very great help and assistance from pharmacists in obtaining these data up throughout England.

**Authorship Contributions**

SNK and VB provided the database for analysis and DIT prepared the initial draft of the paper. All authors approved the final draft. None of the authors were involved in the data collection which was done by the individual pharmacies.

**Conflicts of Interest**

SNK and VB are directors of Howard Foundation Research Ltd. DIT is a consultant for Howard Foundation Holdings Ltd.

**References**


Copyright: ©Thurnham et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.